Esperion Therapeutics Inc (ESPR) Coverage Initiated at Northland Securities
Research analysts at Northland Securities assumed coverage on shares of Esperion Therapeutics Inc (NASDAQ:ESPR) in a report issued on Tuesday. The brokerage set an “outperform” rating and a $72.00 price target on the biopharmaceutical company’s stock. Northland Securities’ price objective would indicate a potential upside of 49.75% from the company’s current price.
Several other brokerages also recently commented on ESPR. Jefferies Group LLC initiated coverage on Esperion Therapeutics in a report on Monday, July 10th. They issued a “hold” rating and a $55.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $60.00 price objective (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. UBS AG reaffirmed a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Finally, Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $48.89.
Esperion Therapeutics (NASDAQ ESPR) opened at 48.08 on Tuesday. The stock has a 50 day moving average price of $47.12 and a 200-day moving average price of $37.64. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $57.38. The firm’s market cap is $1.09 billion.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period last year, the business earned ($0.62) earnings per share. Equities analysts forecast that Esperion Therapeutics will post ($7.33) earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $158,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $162,000. Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at approximately $205,000. Tower Research Capital LLC TRC boosted its stake in shares of Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 4,856 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the last quarter. Institutional investors own 83.33% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Stock Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related stocks with our FREE daily email newsletter.